The FTSE 250 healthcare specialist continues to buy back shares in large volumes as it keeps its discount in check, with biotech dealmaking and clearer US drug-pricing policy supporting its Investment case.
Worldwide Healthcare Trust (LSE:WWH) has kept up an aggressive share buyback programme in recent weeks, repurchasing more than a million shares in a single session this week as it seeks to limit the discount at which its shares trade relative to net asset value. The FTSE 250 investment trust, managed by healthcare specialist OrbiMed, has shrunk its share count dramatically over the past eighteen months through repurchases, while its managers remain constructive on the outlook for global healthcare.
Large-scale repurchases
On 7 October 2026, the trust bought back 1,137,845 shares at 369.15p each, to be held in treasury. Following that purchase, it had 601,665,200 shares in issue, of which 260,720,703 were held in treasury, leaving 340,944,497 shares with voting rights. The latest estimated net asset value, as at the close of Business on 7 October, was 395.43p per share including income, implying the buyback price represented a discount of a little under 7%.
The board's policy is to buy back shares when the discount exceeds 6% on an ongoing basis. In the year to 31 March 2026, the trust repurchased more than 121 million shares at a cost of about £396 million, equivalent to almost a quarter of its Share Capital at the start of the year. The board estimated that buying at an average discount of 7.0% added around 1.8% to NAV total return. A further £35.8 million was spent in the first two months of the current financial year, and shareholders renewed the buyback authority at the July annual general meeting.
Solid year relative to the sector
For the year to March, WWH delivered a NAV total return of 10.0%, compared with just 1.8% for the MSCI World Health Care index in sterling terms, while the share price total return was 13.1%. The discount narrowed from 12.4% to 10.0% over the year. The total Dividend was held at 2.4p per share, as net Revenue fell because of lower exposure to higher-yielding stocks and a smaller portfolio after buybacks.
Dealmaking was a significant driver. Several holdings were acquired during the year, including Exact Sciences by Abbott, Avidity Biosciences by Novartis and Apellis Pharmaceuticals by Biogen, while AstraZeneca and CG Oncology were also solid contributors. The biggest detractors were Boston Scientific, after a revenue shortfall on a key product, and UnitedHealth, which was hit by rising medical costs and regulatory issues and was sold before the year end.
Positioning and policy backdrop
At the end of March, Eli Lilly was the largest holding at 11.3% of the portfolio, followed by Boston Scientific, AstraZeneca, Intuitive Surgical and Edwards Lifesciences. The trust is heavily overweight biotechnology, at nearly a third of NAV against about 11% for the index, and underweight large pharmaceutical companies and healthcare services. It also holds around 10% in emerging markets, mainly China, and uses gearing.
Portfolio managers Sven Borho and Trevor Polischuk have argued that agreements between the US administration and drugmakers on pricing and tariffs have removed much of the policy uncertainty that weighed on the sector, although the regulatory environment at the Food and Drug Administration is less settled following Leadership changes. They expect Patent expiries at large pharmaceutical companies to continue fuelling biotech acquisitions. Risks include the Iran conflict and its effect on energy prices, Tariff implementation, Inflation and interest rates. Half-year results for the period to 30 September are expected in the coming weeks.






Please wait processing your request...